Wire open Last filed CagriSema bone density data at ObesityWeek point to a calcitonin receptor role RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire
UrgentREGNews

Glepaglutide EU approval gives short bowel syndrome a twice weekly GLP 2 drug

The European Commission authorised Zealand Pharma's Zeydovio for adults with short bowel syndrome. In the EASE 1 trial it cut weekly intravenous support more than placebo, and nine patients came off it entirely.

Editorial illustration for the story: Glepaglutide EU approval gives short bowel syndrome a twice weekly GLP 2 drug
Illustration: Peptide Zone. Editorial drawing, not data.

What's new

The European Commission authorised Zeydovio (glepaglutide), a twice weekly GLP 2 analogue, for adults with short bowel syndrome, valid across the EU, Iceland, Liechtenstein and Norway.

Why it matters

Many people with short bowel syndrome depend on intravenous nutrition and fluids for years, with serious risks, and the EASE 1 trial showed the drug can reduce that need.

What's next

Zealand is seeking a commercial partner, full extension results are due in 2027, and the EASE 5 trial is recruiting to support a US application.

Glepaglutide EU approval came on 13 November, when the European Commission granted Zealand Pharma a marketing authorisation for Zeydovio in adults with short bowel syndrome, the Danish company said. The medicine is a long acting analogue of GLP 2, a gut hormone that helps the intestine take up fluid and nutrients. It is injected twice a week from a ready to use pen. The decision follows a positive opinion from the European Medicines Agency's human medicines committee in September.

What the European Commission approved

The authorisation covers adults with short bowel syndrome and is valid in every European Union member state as well as Iceland, Liechtenstein and Norway, according to Zealand. The agency's committee, the CHMP, adopted its positive opinion on 17 September 2026, the EMA Zeydovio page shows. The EMA describes glepaglutide as a long acting version of GLP 2, a peptide that encourages growth of the gut lining. It raises blood flow to the intestine and slows gastric acid release and gut movement, which gives the bowel more time and more surface to absorb what passes through it. The product comes as a single strength solution in a prefilled pen, and the US Food and Drug Administration has given the drug orphan designation for the same condition.

Short bowel syndrome is rare and usually follows surgery that removes a large part of the intestine, or a disease that destroys its function. Many patients cannot absorb enough food and fluid by mouth and depend on parenteral support, meaning nutrition and fluids given straight into a vein, often for many hours on several days each week. Zealand lists sepsis, blood clots, liver damage and kidney problems among the risks that come with long term intravenous feeding. Teduglutide, sold as Revestive, is an older GLP 2 analogue that is already authorised in the European Union for this condition, so glepaglutide is not the first drug of its class. Zealand calls Zeydovio the first ready to use GLP 2 therapy, which is a company claim about its pen format.

EASE 1 trial results behind the decision

The approval rests mainly on EASE 1, a double blind Phase 3 trial in 106 adults with short bowel syndrome and intestinal failure who needed parenteral support at least three days a week. Patients were split evenly between glepaglutide once a week, glepaglutide twice a week and placebo. The main measure was the change in weekly parenteral support volume after 24 weeks. On the twice weekly schedule, weekly volume fell by 5.13 litres, against 2.85 litres on placebo, a difference the company reports as statistically significant. The trial is listed as EASE SBS 1 on ClinicalTrials.gov under the number NCT03690206. Zealand said the benefit was seen whether or not patients still had part of their colon connected to the small bowel.

Among people on the twice weekly schedule, 65.7% cut their weekly parenteral support volume by at least 20%, compared with 38.9% on placebo.

Other measures pointed the same way. Among people on the twice weekly schedule, 65.7% cut their weekly parenteral support volume by at least 20%, compared with 38.9% on placebo. About half of that group, 51.4%, needed intravenous support on at least one day fewer each week, against 19.4% on placebo. Nine patients on glepaglutide stopped parenteral support altogether, five of them on the twice weekly schedule, while nobody on placebo reached that point. Of the 106 patients, 102 finished the trial and 96 moved into a two year extension. Zealand says the drug appeared safe and well tolerated, but its release gives no adverse event rates, so readers cannot yet judge the side effect profile from the public summary alone.

Glepaglutide EU approval and the evidence still to come

Several further studies sit behind the decision. EASE 2 and EASE 3 followed patients for up to two years, and Zealand says interim analyses showed responses that held or improved, with more patients coming off intravenous support. Both trials finished in 2026, and full results are due at scientific meetings in 2027. A smaller mechanistic study, EASE 4, measured how much fluid and energy the gut absorbed. At week 24 it reported a mean rise of 398 grams a day in wet weight absorption and 1,038 kilojoules a day in energy absorption, according to the company. Patients still on treatment have moved into a further extension called EASE 6. The table below lists the main figures released so far, all taken from company and agency documents.

ItemResult or dateSource
CHMP positive opinion17 September 2026EMA
European Commission authorisation13 November 2026Zealand Pharma
EASE 1 weekly support volume cut5.13 litres vs 2.85 litres on placeboZealand Pharma
At least 20% volume cut65.7% vs 38.9% on placeboZealand Pharma
Patients weaned off support9 on glepaglutide, 0 on placeboZealand Pharma
US statusEASE 5 trial recruiting, orphan designationZealand Pharma

The main limits come from the size and length of the core trial. EASE 1 enrolled about one hundred people over 24 weeks, which is normal for a rare disease but leaves wide uncertainty around rarer harms. Its main measure is the volume of intravenous support, a practical goal for patients, but not a direct count of infections, liver damage or survival. Most efficacy figures in the release come from the twice weekly arm, and the once weekly results are not described in the same detail. The EMA assessment report, once published, will set out the agency's own reading of the benefits and risks. Further readouts and the questions to ask of them are collected on the Peptide Zone trials desk.

US filing and commercial plans

Zeydovio is not approved in the United States. Zealand says EASE 5, a Phase 3 trial meant to give further confirmatory evidence for a US application, is recruiting well, but it has not given a filing date. The company also has no sales partner yet. It says it is in talks with possible partners for global commercialisation, and it has not announced launch dates for any European country. Pricing and reimbursement will be set country by country, so access for patients will depend on national health technology assessments that have not yet started in public. Until then, the European authorisation alone does not mean that hospitals in each country can prescribe the drug under their usual funding rules.

Chief executive Adam Steensberg called the approval "the first major advancement in treatment in more than a decade" for people with the condition in Europe, and said the focus "now turns to finding the right partner". Zealand is better known to obesity watchers for the amylin drug petrelintide, which it develops with Roche, as covered in our report on the Roche petrelintide amylin bet. The glepaglutide EU approval gives the company its first approved product from its own GLP 2 work and a rare disease asset that does not depend on the obesity market. Other agency decisions on peptide medicines are tracked on the Peptide Zone regulators desk.

Conclusion

The glepaglutide EU approval gives adults with short bowel syndrome a second GLP 2 analogue, given twice a week from a ready to use pen. In EASE 1 it cut weekly intravenous support more than placebo and freed a small number of patients from it entirely. Longer extension data, the EMA assessment report and a commercial partner will decide how quickly patients in Europe see the drug, while the United States waits on EASE 5.

More from the wire

Same thread first, then the same desk.